Activ Surgical01.18.22
Activ Surgical, a digital surgery pioneer, has raised $45 million in a Series B financing round. The Series B round was led by Cota Capital, a multi-stage investment firm focused on private and public modern enterprise technology companies. Seven new investors, including BAM Funds, Magnetar Capital, MINT Venture Partners, Castor Ventures, Dream One Vision, and NVIDIA, join existing investors DNS Capital, Tao Capital Partners, LRVHealth, Rising Tide VC, GreatPoint Ventures (GPV) and ARTIS Ventures to close out the Series B round of financing. To date, Activ Surgical has raised a total of $77 million.
“Activ Surgical is on a mission to empower surgeons with the critical information they need,” said Renee Yao, Global Healthcare AI Startups lead at NVIDIA. “Their team is fusing together technologies to enable real-time intelligence and visualization for the operating room of the future.”
Activ Surgical is building a hardware-agnostic platform, including the ActivInsights augmented reality (AR)-based software suite, to enable autonomous and collaborative surgery through the integration of computer vision, artificial intelligence (AI), machine learning (ML), AR and robotics. The company will use this Series B financing round to support the commercial availability of the ActivInsights software suite, including the first Insight—an AR-based overlay that displays tissue perfusion in real time without the use of traditional dyes. Activ Surgical will also use the funds to support commercialization in the United States, pursue a CE mark in support of the global rollout, and further enhance the ActivInsights software platform and to develop its first ML-based insights.
In conjunction with this fundraise, the Activ Surgical Board of Directors will expand to include Bobby Yazdani, founder and partner from Cota Capital. Yazdani has more than three decades of entrepreneurial experience, including more than 20 years of investing in technology companies in Silicon Valley, and formed Cota Capital in 2014. Yazdani will serve on Activ Surgical’s Board of Directors alongside current board members Ameena El-Bibany, ARTIS Ventures; Will Cowen, LRVHealth; Emily Casey, DNS Capital; Ashok Krishnamurthi, Great Point Ventures; Paul Meister, independent board member; Dr. Peter Kim, Activ Surgical; and Todd Usen, Activ Surgical.
“Activ Surgical is on pace to solve the ‘last mile’ challenge for the surgical field and revolutionize the operating room as we know it,” said Yazdani. “The company’s cutting-edge product portfolio, coupled with its leadership team and staff, has the potential to deliver surgery, regardless of geography or economic status, while helping to save lives and reduce medical complications. We are thrilled to be the lead investor on this Series B fundraise and are excited about what the future holds for the company and its technology.”
Activ Surgical is the pioneering digital surgery company that completed the world’s first autonomous robotic surgery of soft tissue in 2018. The company is revolutionizing surgical vision, enabling a future of augmented reality-based and artificial intelligence-driven surgery that is safe, smart, and accessible to all. Its patent-protected surgical software platform—ActiveEdge–is being designed to reduce unintended and preventable surgical errors by enhancing a surgeon’s intraoperative decision making via the aggregation of surgical data from around the world. Activ Surgical is privately held, and backed by DNS Capital, GreatPoint Ventures (GPV), Artis Ventures, Tao Capital Partners, LRVHealth, Rising Tide VC, SONY Innovation Fund and 8VC.
“Activ Surgical is on a mission to empower surgeons with the critical information they need,” said Renee Yao, Global Healthcare AI Startups lead at NVIDIA. “Their team is fusing together technologies to enable real-time intelligence and visualization for the operating room of the future.”
Activ Surgical is building a hardware-agnostic platform, including the ActivInsights augmented reality (AR)-based software suite, to enable autonomous and collaborative surgery through the integration of computer vision, artificial intelligence (AI), machine learning (ML), AR and robotics. The company will use this Series B financing round to support the commercial availability of the ActivInsights software suite, including the first Insight—an AR-based overlay that displays tissue perfusion in real time without the use of traditional dyes. Activ Surgical will also use the funds to support commercialization in the United States, pursue a CE mark in support of the global rollout, and further enhance the ActivInsights software platform and to develop its first ML-based insights.
In conjunction with this fundraise, the Activ Surgical Board of Directors will expand to include Bobby Yazdani, founder and partner from Cota Capital. Yazdani has more than three decades of entrepreneurial experience, including more than 20 years of investing in technology companies in Silicon Valley, and formed Cota Capital in 2014. Yazdani will serve on Activ Surgical’s Board of Directors alongside current board members Ameena El-Bibany, ARTIS Ventures; Will Cowen, LRVHealth; Emily Casey, DNS Capital; Ashok Krishnamurthi, Great Point Ventures; Paul Meister, independent board member; Dr. Peter Kim, Activ Surgical; and Todd Usen, Activ Surgical.
“Activ Surgical is on pace to solve the ‘last mile’ challenge for the surgical field and revolutionize the operating room as we know it,” said Yazdani. “The company’s cutting-edge product portfolio, coupled with its leadership team and staff, has the potential to deliver surgery, regardless of geography or economic status, while helping to save lives and reduce medical complications. We are thrilled to be the lead investor on this Series B fundraise and are excited about what the future holds for the company and its technology.”
Activ Surgical is the pioneering digital surgery company that completed the world’s first autonomous robotic surgery of soft tissue in 2018. The company is revolutionizing surgical vision, enabling a future of augmented reality-based and artificial intelligence-driven surgery that is safe, smart, and accessible to all. Its patent-protected surgical software platform—ActiveEdge–is being designed to reduce unintended and preventable surgical errors by enhancing a surgeon’s intraoperative decision making via the aggregation of surgical data from around the world. Activ Surgical is privately held, and backed by DNS Capital, GreatPoint Ventures (GPV), Artis Ventures, Tao Capital Partners, LRVHealth, Rising Tide VC, SONY Innovation Fund and 8VC.